A venture capital investor primarily makes angel investments in seed-stage companies and works hands-on with portfolio companies to facilitate regulatory approval and commercialization. Typical initial check size is in the $500–750K range, with tranche investments possible beyond this amount. The firm is open to global opportunities.
The firm focuses on therapeutics companies in the early stages of drug discovery and development. Current areas of interest include CNS and neurodegenerative diseases, oncology, and pulmonary diseases pursued with novel approaches. While the firm works primarily with pre-clinical opportunities, it may consider other indications from time to time.
The firm’s long-term strategy is to help companies progress toward Phase II readiness for pre-clinical assets. With broad expertise in regulatory and toxicology matters, the firm takes a hands-on approach to supporting portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment